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The role of genetic polymorphisms in pediatric brain tumor (PBT) etiology is poorly 
understood. We hypothesized that single nucleotide polymorphisms (SNPs) identified in 
genome-wide association studies (GWAS) on adult glioma would also be associated with 
PBT risk. The study is based on the Cefalo study, a population-based multicenter case-control 
study. Saliva DNA from 245 cases and 489 controls, aged 7-19 years at diagnosis/reference 
date, was extracted and genotyped for 29 SNPs reported by GWAS to be significantly 
associated with risk of adult glioma. Data were analyzed using unconditional logistic 
regression. Stratified analyses were performed for two histological subtypes: astrocytoma 
alone and the other tumor types combined.  The results indicated thatfour SNPs, CDKN2BAS 
rs4977756 (p=0.036), rs1412829 (p=0.037), rs2157719 (p=0.018), and rs1063192 (p=0.021), 
were associated with an increased susceptibility to PBTs, whereas the TERT rs2736100 was 
associated with a decreased risk (p=0.018). Moreover, the stratified analyses showed a 
decreased risk of astrocytoma associated with RTEL1 rs6089953, rs6010620, and rs2297440 
(ptrend=0.022, ptrend=0.042, ptrend=0.029, respectively) as well as an increased risk of this 
subtype associated with RTEL1 rs4809324 (ptrend=0.033). In addition, SNPs rs10464870 and 
rs891835 in CCDC26 were associated with an increased risk of non-astrocytoma tumor 
subtypes (ptrend=0.009, ptrend=0.007, respectively). Our findings indicate that SNPs in 
CDKN2BAS, TERT, RTEL1, and CCDC26 may be associated with the risk of PBTs. 
Therefore, we suggest that pediatric and adult brain tumors might share common genetic risk 
factors and similar etiological pathways. 
 
 
 
Summary 
 
 
4 
 
The role of genetic polymorphisms in pediatric brain tumor (PBT) etiology is poorly 
understood. In this study, we tested the hypothesis that single nucleotide polymorphisms 
identified by genome-wide association studies on adult glioma are also associated with PBT 
risk. 
Introduction 
Brain tumors are the second most common type of pediatric cancer and the leading cause of 
childhood cancer mortality. The etiology of pediatric brain tumors (PBTs) is poorly 
understood (1). As in adults (2), the only established risk factors for brain tumors in children 
are exposure to high doses of ionizing radiation and several inherited disorders, and these 
cause only a minority of cases. Therefore, it is likely that brain tumorigenesis results from 
complex interactions between genetic and epigenetic variations in concert with exposure to 
environmental factors (1). 
Although large genetic studies on adult brain tumors have been conducted (3-7), very few and 
only small studies of brain tumors in children and adolescents have been reported (8-11). In 
the last few years, four genome-wide association studies (GWAS) on adult glioma identified 
seven susceptibility loci at 5p15.33 (TERT), 8q24.21 (CCDC26), 9p21.3 (CDKN2A-
CDKN2B), 20q13.33(RTEL1), 11q23.3 (PHLDB1), and 7p11.2 (EGFR) (4-7). However, 
limited data are available on the role of genetic polymorphisms in the etiology of PBTs, 
probably because of difficulties in collecting a sufficient number of DNA samples. 
Considering this lack of knowledge about genetic risk factors for brain tumors in children, it 
is important to identify germ-line DNA polymorphisms that might influence the susceptibility 
to PBTs.  
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The aim of this study, based on the largest series of PBT cases to date, was to test the 
hypothesis that the single nucleotide polymorphisms (SNPs) identified by GWAS on adult 
glioma are also associated with the risk of brain tumors in children. 
Materials and methods 
Study population and procedures 
This study is based on the Cefalo study, a large, international, population-based, case-control 
study of brain tumors in children and adolescents conducted in centers in Sweden, Denmark, 
Norway, and Switzerland. All centers  followed a common protocol for data collection, as 
described in more detail elsewhere (12,13). Eligible cases were children aged 7-19 years 
during the period 1 April  2004 to 31 August  2008, diagnosed with a primary intracranial 
brain tumor defined according to the International Classification of Childhood Cancer, third 
edition (ICCC-3) (14), group III, restricted to ICD-O-3 location C71 and subclassified 
according to the fourth edition of the World Health Organization(WHO)classification of 
tumors of the central nervous system(15). Medulloblastoma cases will be the subject of a 
separate study, and therefore have been excluded from the present analysis. Two controls per 
case were randomly selected from the general population matched to the case by age, sex, and 
geographical region. Interviews were conducted with 352 (82%) cases and 646 (71%) 
controls. Participants with neurofibromatosis or tuberous sclerosis were excluded from the 
analyses. The study was approved by the national data protection boards and ethical 
committees in all participating countries, and written informed consent was obtained from all 
participants and/or their parents. 
The Oragene self-collection kit (DNA Genotek, Ottawa, ON, Canada) was used for saliva 
collection and DNA extraction, following the manufacturer’srecommended protocol. DNA 
samples are stored at the KarolinskaInstitutetBiobank. The DNA yield was quantitated by 
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using PicoGreen (Invitrogen, Carlsbad, CA, USA). Overall, saliva DNA from 245 cases and 
489 controls was included in this study.  
SNP selection and genotyping 
A total of 29 SNPs reported by GWAS to be significantly associated with risk of adult glioma 
were selected for genotyping (4-7). Genotyping was performed at the Mutation Analysis core 
Facility (MAF), Clinical Research Centre, Huddinge University Hospital, Stockholm, 
Sweden, with staff blinded to sample status, using the SequenomiPlex Gold platform with 
matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry. 
The average success rate was 97% and the concordance rate for duplicate genotyping was 
100%.  
Statistical analysis 
The consistency of allele frequencies with Hardy-Weinberg equilibrium (HWE) was assessed 
in the controls for all SNPs using the χ2 goodness-of-fit test, and p<0.001 was considered 
statistically significant. Analyses were performed based on the subset of Cefalo subjectswho 
provided saliva sample.Unconditional logistic regression was used to estimate the association 
between SNPs and PBT susceptibility based on the Cochran–Armitage trend test of additivity 
(trend) as well as dominant (DOM) and recessive (REC) models, with adjustment for the 
matching variables (age, sex, and country). The allelic frequencies of the genotyped SNPs 
were compared between cases and controls using the χ2 test. Analyses were also conducted 
stratified byastrocytoma alone and the combination of other tumor types, including 
ependymoma, intracranial embryonal tumors (except medulloblastoma), other gliomas, other 
specified intracranial neoplasms, and unspecified intracranial neoplasms. Country specific 
analyses were performed to assess consistency across countries.The Wald test was used to 
evaluate the significance of interactions between SNPs and demographic variablesand D´, a 
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measure of the linkage disequilibrium (LD) between the genotyped SNPs, was 
calculated.Haploblocks were defined based on the default LD block parameters in Haploview 
v4.2.  Haplotype analyses were performed for the haplotype blocks harboring the SNPs that 
were found to be associated with PBTs. Haplotypes with a frequency of >1% were considered 
in the analyses. The effects of specific haplotypes were analyzed if the distribution of all the 
haplotypes was suggestively different between cases and controls (p<0.05 for all PBTs; p<0.1 
for subgroup analyses).  Selection of SNPs for the analyses was based on a priori knowledge 
from GWAS on adults, and therefore odds ratios (ORs) are presented with 95% confidence 
intervals (CIs). The possibility of false-positive findings was, however, considered by also 
providing the reference p value for an experiment-wide significance with Bonferroni 
correction. The analyses were performed using PLINK v1.07 (16) and SAS statistical 
software version 9.3 (SAS Institute, Inc., Cary, NC, USA). 
Results 
We successfully genotyped 29 SNPs in 245 cases and 489 controls. The distributions of allele 
frequencies in the controls were in agreement with the Hardy-Weinberg equilibrium. Table 1 
shows demographic characteristics of cases and controls, and the distributions of diagnostic 
subtypes. The age and sex distributions were similar in cases and controls. More than 50% of 
cases were diagnosed with astrocytoma. No significant interactions were detected between 
SNPs and confounders including age, sex and country (Table 2).  
As shown in Table 2, TERT rs2736100 A allele was associated with a decreased risk of PBTs 
(ORDOM 0.66 [95% CI 0.46-0.93], p=0.018), whereas the SNPs rs4977756 G allele (ORDOM 
1.45 [95% CI 1.03-2.06], p=0.036), rs1412829 G allele (ORDOM 1.45 [95% CI 1.02-2.05], 
p=0.037), rs2157719 C allele (ORDOM 1.53 [95% CI 1.08-2.19], p=0.018), and rs1063192 G 
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allele (ORDOM 1.53 [95% CI 1.07-2.19], p=0.021) in CDKN2BAS were associated with 
increased susceptibility to this tumors.  
The stratified analyses of two histological subtypes indicated that the risk effects of 
CDKN2BAS rs1063192, rs2157719, rs1412829, and rs4977756 remained significant in 
patients with astrocytoma (ptrend=0.036, ptrend=0.034, ptrend=0.044, and ptrend=0.023, 
respectively), whereas the protective effect of TERT rs2736100 was more evident in patients 
with other brain tumor subtypes (ORDOM 0.53 [95% CI 0.34-0.85], p=0.007). Moreover, the 
stratified analyses showed a decreased risk of astrocytoma associated with the polymorphisms 
RTEL1 rs6089953 A allele, rs6010620 A allele, and rs2297440 T allele (ptrend=0.022, 
ptrend=0.042, and ptrend=0.029, respectively), as well as an increased risk of this subtype 
associated with the C alleleof RTEL1 rs4809324 (ptrend=0.033). In addition, an increased risk 
of non-astrocytoma tumor subtypes was associated with the SNPs rs10464870 C allele and 
rs891835 G allele in CCDC26 (ptrend=0.009 and ptrend=0.007, respectively) (Table 3). 
The non-significant findings, possibly resulting from the limited statistical power of the study, 
are shown in the online appendix Tables S1-S3 and the raw data showing the number of cases 
and controls for each genotype of significant SNPs are reported in Table S4. 
Strong LD (D´≥0.95) was observed between three of the genotyped SNPs in CDKN2BAS 
(rs1412829, rs2157719, and rs1063192), and four SNPs in RTEL1 (rs6089953, rs6010620, 
rs2297440, and rs4809324). For each of the two blocks, three haplotypes with frequency of 
>1% were found. The distribution of haplotypes was different for PBT patients compared to 
controls for the CDKN2BAS block (χ2=7.0, df=2, p=0.030) and showed a tendency to be 
different for the RTEL1 block (χ2=5.9, df=2, p=0.053). The most common haplotype (ATA) 
of CDKN2BAS SNPs had a significant protective effect compared with the other haplotypes 
combined (OR 0.75 [95% CI 0.60-0.93], p=0.009) whereas the second most common 
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haplotype (GCG) had a significant risk effect (OR 1.32 [95% CI 1.06-1.64], p=0.012). The 
haplotype analyses suggested an increased risk of PBTs by increasing the numberof risk 
alleles in CDKN2BAS andRTEL1SNPs. In the astrocytoma subgroup, the same haploblocks 
and haplotypes with frequencies of >1% were detected. However, in this subgroup, the 
distribution of haplotypes in the RTEL1 block was significantly different between patients and 
controls (χ2=9.0, df=2, p=0.011) while this difference was not statistically significant in the 
CDKN2BAS block (χ2=5.7, df=2, p=0.059). In the astrocytoma subgroup, a significant 
protective effect was observed for the most common haplotype (ATA) of CDKN2BAS SNPs 
compared with the other haplotypes combined (OR 0.73 [95% CI 0.56-0.95], p=0.021) 
whereas the second most common haplotype (GCG) showed a significant risk effect (OR 1.34 
[95% CI 1.02-1.76], p=0.036). Moreover, in the RTEL1 block, the second most common 
haplotype (AATT) had a significant protective effect compared with the other haplotypes 
combined (OR 0.67 [95% CI 0.47-0.95], p=0.023) whereas the third most common haplotype 
(GGCC) had a significant risk effect (OR 1.57 [95% CI 1.06-2.34], p=0.026) (Table 4). 
Overall, we performed 116 testing procedures as described above. When the Bonferroni 
correction is applied, the reference p value is 0.0004 for an experiment-wide significance 
level of 0.05, and 0.0009 for a significance level of 0.10; none of the observed associations 
met these limits.The consistency of results across countries wasinvestigated and the results of 
stratified analyses are reported in the online appendix Tables S5-S8.No significant differences 
between countries were observed.Discussion 
The results of this study indicate that several SNPs associated with adult glioma risk are also 
associated with the risk of PBTs. Our findings suggest that SNPs rs4977756 G allele, 
rs1412829 G allele, rs2157719 C allele, and rs1063192 G allele in CDKN2BAS may increase 
the risk of PBTs, whereas the A alleleof TERT rs2736100 polymorphism may confer 
protection against PBTs. In addition, polymorphisms rs6089953 A allele, rs6010620 A allele, 
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and rs2297440 T allele in RTEL1 were associated with decreased susceptibility to 
astrocytoma, whereas the C allele of RTEL1 rs4809324 was associated with an increased risk 
of this subtype. Furthermore, an increased risk of non-astrocytoma tumor subtypes associated 
with polymorphisms CCDC26 rs10464870 C allele and rs891835 G allelewas detected. Our 
findings suggest that genetic risk profiles of PBTs differ by histology. 
To our knowledge, this study represents the largest series of pediatric brain tumor cases 
assembled for genetic association testing to date. The association between the 29 SNPs 
investigated in this study and the risk of PBTs has not been examined in previous studies (8-
11). The SNPs were selected a priori for analyses in this study based on findings in GWAS on 
adult glioma, and our significant findings of associations between SNPs in CDKN2BAS, 
TERT, RTEL1,and CCDC26 and risk of PBTs were consistent with findings on adult brain 
tumors with respect to the direction of ORs for the minor alleles (4-7).  
CDKN2BAS (ANRIL) encodes antisense non-coding RNA in the INK4 locus which is a long 
non-coding RNA (ncRNA). The exact function of CDKN2BAS is unclear, but it is known to 
be involved in regulating the expression of CDKN2A and CDKN2B genes that encode cyclin-
dependent kinase inhibitors and block cell cycle division during the G1/S phase. Therefore, 
CDKN2BAS has a regulatory role in the context of cellular proliferation, and its alterations 
result in abnormal self-renewing capabilities typical of cancer cells (17,18). Germ-line 
mutations in CDKN2BAS predispose to a wide variety of human cancers (19,20). 
_ENREF_17_ENREF_4 
Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase that maintains 
telomere by adding telomeric repeat sequences onto chromosome ends. Telomerase 
expression can prevent telomere erosion in most eukaryotic cells, and cancer cells can prevent 
telomere loss through the abnormal upregulation of telomerase (21). _ENREF_18 The mutant 
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allele of TERT rs2736100, which is an intronic polymorphism, may downregulate telomerase 
expression and consequently decrease the risk of brain tumors.   
RTEL1 producesregulator of telomere elongation helicase 1 which is essential for telomere 
maintenance and genome stability by preventing homologous recombination (22). 
Polymorphisms in RTEL1 are correlated withhigh grade glioma in adults (4,5,7,23). 
_ENREF_4In contrast, CCDC26 variations are associated with low grade tumors (4,5,23). 
CCDC26 encodes a retinoic acid–dependent regulator of cell differentiation and death. 
CCDC26increases apoptosis induced by death stimuli in neuroblastoma cells (24) and in 
glioblastoma cells with downregulation of telomerase activity (25). 
The majority of genetic variations found in this study to be associated with the risk of PBTs 
are related to telomerase activity which has an important role in the initiation and progression 
of gliomas(26). Moreover, it has been shown that telomerase expression is related to high 
grade gliomas and poor survival (27,28). Thus, telomerase could be considered as a 
therapeutic target for brain tumors (29,30). 
The aim of this study was to provide evidence of the associations between SNPs and PBT 
risk, and not to investigate the mechanisms behind such associations; nevertheless the fact 
that we did not consider the effect of environmental risk factors represents a limitation of this 
work. Therefore, additional studies are needed to examine potentially relevant gene-
environment interactions and to explore the mechanisms through which these genetic 
polymorphisms influence cancer susceptibility. 
The present study was conducted based on a specific hypothesis that may lead to detection of 
clinically meaningful risk and protective factors. Moreover, the selection of SNPs for analysis 
was based on a priori knowledge from GWAS on adults, and therefore Bonferroni correction 
may be overly conservative and may make researchers miss important findings (31). To be 
 
 
12 
 
able to evaluate potential false-positive findings, reference p values with Bonferroni 
corrections have been presented and the consistency of results across four countries has 
beenreported. No significant differences between countries were observed.Replication studies 
are necessary to confirm these results in larger sample sizes. 
In conclusion, the present findings indicate that SNPs in CDKN2BAS are associated 
withincreased susceptibility to PBTs, whereas TERT polymorphisms may decrease the risk of 
these tumors. Moreover, polymorphisms in RTEL1 and CCDC26 genes are associated with 
the risk of astrocytoma and non-astrocytoma subtypes, respectively. Thus, we suggest that 
pediatric and adult brain tumors might share common genetic risk factors and similar 
etiological pathways.  
Supplementary material 
Supplementary Tables S1-S3 can be found at http://carcin.oxfordjournals.org/. 
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Table 1. Characteristics of cases and controls 
Characteristics  Cases Controls  
No. of participants 245 489 
 
 
17 
 
Sex   
Males 136 (56%) 261 (53%) 
Females 109 (44%) 228 (47%) 
Age-group (at reference date)   
7-9 years old 48 (20%) 112 (23%) 
10-14 years old 108 (44%) 219 (45%) 
15-19 years old 89 (36%) 158 (32%) 
Country   
Sweden 106 (43%) 174 (36%) 
Norway 24 (10%) 62 (13%) 
Denmark 62 (25%) 134 (27%) 
Switzerland 53 (22%) 119(24%)  
Type of tumor (ICCC-3 group III)a   
Astrocytoma (IIIb) 134 (55%)  
Pilocyticastrocytoma 93  
Supependymalgiant cell astrocytoma 5  
Pleomorphicxanthoastrocytoma 4  
Diffuse astrocytoma 13  
Anaplastic astrocytoma 11  
Fibrillaryastrocytoma 2  
Glioblastoma 5  
Giant cell glioblastoma 1  
Other gliomas (IIId) 20 (8%)  
Malignantglioma 11  
Oligoastrocytoma 2  
Oligodendroglioma 6  
Anaplastic oligodendroglioma 1  
Ependymoma (IIIa) 19 (8%)  
Subependymoma 2  
Choroidplexuspapilloma 4  
Choroidplexuscaricinoma 1  
Ependymoma 7  
Papillaryependymoma 1  
Anaplastic ependymoma 4  
Intracranial embryonal tumors (IIIc) 7 (3%)  
CNS primitive neuroectodermaltumor 6  
Neuroepithelioma 1  
Other specified intracranial neoplasms (IIIe) 49 (20%)  
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Germinoma 7  
Yolksactumor 1  
Teratoma, mature 1  
Haemangioblastoma 1  
Desmoplastic infantile ganglioglioma 2  
Dysembryoplastic neuroepithelialtumor 6  
Ganglioglioma 26  
Anaplasticganglioglioma 1  
Centrolneurocytoma 3  
Neurilemoma 1  
Unspecified intracranial neoplasm (IIIf) 16 (6%)  
 
a: Restricted to ICD-O-3 location C71, subclassified according to WHO histological  
subclassification, 2007; patients with neurofibromatosis and tuberous sclerosis were excluded.  
19 
 
Table 2. Summary results for SNPs associated with pediatric brain tumors 
 
 
 
SNP Chr. Gene Location (bp) 
Minor
allele 
MAFa 
in cases
MAFa in 
controls Model OR
b 95% CI P CHISQ Pinteractionc 
             
rs2736100 5 TERT 1286516 A 0.47 0.50 Dominant 0.66  0.46-0.93 0.018  0.702 
       Recessive 1.19  0.82-1.71 0.359   
       Additive 0.89 0.72-1.12 0.351   
       Allelic   0.333 0.94  
 rs1063192 9 CDKN2BAS 22003367 G 0.52 0.45 Dominant 1.53  1.07-2.19 0.021  0.889 
  CDKN2B     Recessive 1.36 0.95-1.95 0.095   
       Additive 1.31 1.05-1.63 0.015   
       Allelic   0.009 6.64  
rs2157719 9 CDKN2BAS 22033366 C 0.51 0.44 Dominant 1.53  1.08-2.19 0.018  0.825 
       Recessive 1.36  0.94-1.97 0.099   
       Additive 1.32 1.06-1.64 0.014   
       Allelic   0.009 6.67  
rs1412829 9 CDKN2BAS 22043926 G 0.50 0.43 Dominant 1.45  1.02-2.05 0.037  0.734 
       Recessive 1.38 0.95-1.99 0.089   
       Additive 1.29 1.04-1.61 0.021   
       Allelic   0.014 6.04  
rs4977756 9 CDKN2BAS 22068652 G 0.49 0.42 Dominant 1.45  1.03-2.06 0.036  0.954 
       Recessive 1.30 0.89-1.91 0.176   
       Additive 1.27  1.02-1.59 0.032   
       Allelic   0.024 5.09  
20 
 
 
 
a: MAF=Minor Allele Frequency          b: ORadjusted for age, sex, and countryc: P value for interactions between SNPs and demographic 
variables including age, sex and country 
21 
 
Table 3. Summary results for SNPs associated with pediatric brain tumors stratified by histological subtypes 
SNP Chr. Gene Location (bp) Minor allele 
MAFa 
in cases 
MAFa in 
controls Model OR
b 95% CI P CHISQ 
Astrocytoma            
 rs1063192 9 CDKN2BAS 22003367 G 0.52 0.45 Dominant 1.84  1.15-2.94 0.011  
  CDKN2B     Recessive 1.21 0.76-1.91 0.419  
       Additive 1.34 1.02-1.76 0.036  
       Allelic   0.038 4.29 
rs2157719 9 CDKN2BAS 22033366 C  0.51 0.44 Dominant 1.75  1.11-2.77 0.016  
       Recessive 1.26  0.79-1.99 0.329  
       Additive 1.34 1.02-1.76 0.034  
       Allelic   0.035 4.43 
rs1412829 9 CDKN2BAS 22043926 G 0.50 0.43 Dominant 1.64  1.05-2.57 0.029  
       Recessive 1.28 0.81-2.03 0.294  
       Additive 1.32 1.01-1.74 0.044  
       Allelic   0.043 4.09 
rs4977756 9 CDKN2BAS 22068652 G 0.5 0.42 Dominant 1.85  1.17-2.91 0.008  
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       Recessive 1.25  0.78-2.01 0.358  
       Additive 1.38  1.05-1.82 0.023  
       Allelic   0.025 5.02 
rs6089953 20 RTEL1 62291008 A 0.18 0.25 Dominant 0.64  0.43-0.96 0.032  
       Recessive 0.49  0.19-1.31 0.157  
       Additive 0.67  0.48-0.95 0.022  
       Allelic   0.019 5.46 
rs6010620 20 RTEL1 62309839 A 0.19 0.25 Dominant 0.66  0.44-0.99 0.048  
       Recessive 0.59  0.24-1.45 0.254  
       Additive 0.71  0.50-0.99 0.042  
       Allelic   0.039 4.27 
rs2297440 20 RTEL1 62312299 T 0.17 0.24 Dominant 0.64 0.41-0.98 0.038  
       Recessive 0.52  0.19-1.37 0.187  
       Additive 0.68 0.47-0.96 0.029  
       Allelic   0.023 5.18 
rs4809324 20 RTEL1 62318220 C 0.15 0.10 Dominant 1.54 0.98-2.39 0.060  
       Recessive 2.94  0.78-11.14 0.112  
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       Additive 1.54 1.04-2.28 0.033  
              Allelic     0.029 4.74 
Other             
rs2736100 5 TERT 1286516 A 0.44 0.50 Dominant 0.54  0.34-0.85 0.007  
       Recessive 1.07  0.64-1.77 0.802  
       Additive 0.78  0.57-1.07 0.122  
       Allelic   0.139 2.19 
rs10464870 8 CCDC26 130477823 C 0.32 0.23 Dominant 1.70  1.11-2.60 0.014  
       Recessive 1.78  0.87-3.66 0.115  
       Additive 1.53  1.11-2.11 0.009  
       Allelic   0.004 8.11 
rs891835 8 CCDC26 130491752 G 0.34 0.24 Dominant 1.59  1.04-2.44 0.032  
       Recessive 2.32  1.18-4.57 0.015  
       Additive 1.55  1.13-2.14 0.007  
       Allelic   0.003 8.65 
a: MAF=Minor Allele Frequency          b: ORadjusted for age, sex, and country   
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Table 4. Haplotype analysis of SNPs in CDKN2BAS and RTEL1 
SNPs Haplotype Frequency ORa 95% CI P 
CDKN2BAS: rs1412829, rs2157719, rs1063192 ATA 0.52 0.75 0.60-0.93 0.009 
 GCG 0.45 1.32 1.06-1.64 0.012 
 ATG 0.02 0.89 0.56-1.43 0.814 
RTEL1: rs6089953, rs6010620, rs2297440, rs4809324 GGCT 0.65 1.03 0.81-1.32 0.787 
 AATT 0.23 0.79 0.61-1.02 0.074 
 GGCC 0.11 1.39 0.99-1.95 0.055 
Astrocytoma      
CDKN2BAS: rs1412829, rs2157719, rs1063192 ATA 0.53 0.73 0.56-0.95 0.021 
 GCG 0.44 1.34 1.02-1.76 0.036 
 ATG 0.02 0.79 0.21-2.94 0.725 
RTEL1: rs6089953, rs6010620, rs2297440, rs4809324 GGCT 0.65 1.06 0.81-1.39 0.676 
 AATT 0.23 0.67 0.47-0.95 0.023 
 GGCC 0.11 1.57 1.06-2.34 0.026 
 
a: Odds ratio for haplotype compared with all other haplotypes adjusted for age, sex, and country 
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Table S1. Summary results for SNPs unassociated with pediatric brain tumors 
 
SNP Chr. Location (bp) 
Minor 
allele 
MAF
ψ
 in 
cases 
MAF
ψ
 in 
controls 
Model    OR
£
    95% CI    P CHISQ 
    
  
     
rs7530361 1 100462860 C 0.144    0.1656 Dominant 0.7977 0.5631-1.13 0.2032 
 
    
  Recessive 0.9425 0.347-2.56 0.9075 
 
    
  Additive 0.8339 0.6127-1.135 0.2479 
 
    
  Allelic 
  
0.2881 1.129 
    
  
     
rs501700 1 100520311 A 0.148 0.1607 Dominant 0.861 0.5991-1.238 0.4188 
 
    
  Recessive 0.9696 0.3565-2.637 0.9518 
 
    
  Additive 0.8895 0.6477-1.222 0.4693 
 
    
  Allelic 
  
0.5454 0.3657 
    
  
     
rs2072532 2 40366301 G 0.4604    0.4317 Dominant 1.395 0.99-1.967 0.05706 
 
    
  Recessive 1.008 0.6833-1.487 0.9679 
 
    
  Additive 1.152 0.9256-1.434 0.2048 
 
    
  Allelic 
  
0.3019 1.066 
    
  
     
rs2853676 5 1288547 T 0.2845    0.2763 Dominant 0.9819 0.7169-1.345 0.9092 
 
    
  Recessive 1.292 0.7517-2.222 0.3535 
 
    
  Additive 1.04 0.8165-1.324 0.7516 
 
    
  Allelic 
  
0.7426 0.1079 
    
  
     
rs6869535 5 40597618 A 0.1667    0.1632 Dominant 0.9696 0.6894-1.364 0.8591 
 
    
  Recessive 1.495 0.5472-4.086 0.4328 
 
2 
 
    
  Additive 1.011 0.7462-1.37 0.9438 
 
    
  Allelic 
  
0.8664 0.02829 
    
  
     
rs10079250 5 149450132 C 0.06042   0.06394 Dominant 0.9751 0.6051-1.571 0.9175 
 
    
  
Recessive 
1.061e-
009 
0-inf 0.9993 
 
    
  Additive 0.9558 0.5977-1.529 0.8503 
 
    
  Allelic 
  
0.7951 0.06744 
    
  
     
rs2252586 7 54978924 T 0.2562    0.2901 Dominant 0.7588 0.5537-1.04 0.08594 
 
    
  Recessive 1.106 0.6142-1.991 0.7375 
 
    
  Additive 0.8544 0.6639-1.1 0.2214 
 
    
  Allelic 
  
0.178 1.815 
    
  
     
rs6969537 7 55082418 A 0.1402    0.1224 Dominant 1.239 0.863-1.778 0.2457 
 
    
  Recessive 0.6967 0.1371-3.541 0.6631 
 
    
  Additive 1.184 0.8456-1.657 0.3259 
 
    
  Allelic 
  
0.3426 0.9005 
    
  
     
rs11979158 7 55159349 G 0.1757    0.1576 Dominant 1.16 0.8276-1.626 0.3889 
 
    
  Recessive 1.291 0.4567-3.648 0.6303 
 
    
  Additive 1.151 0.8507-1.556 0.3625 
 
    
  Allelic 
  
0.381 0.7676 
    
  
     
rs10488631 7 128594183 C 0.1125    0.1174 Dominant 0.9275 0.6301-1.365 0.7028 
 
    
  Recessive 0.7406 0.2226-2.464 0.6245 
 
    
  Additive 0.9194 0.6529-1.295 0.6305 
 
    
  Allelic 
  
0.7843 0.07492 
    
  
     
3 
 
rs12531711 7 128617466 G 0.1176     0.117 Dominant 0.9908 0.6659-1.474 0.9636 
 
    
  Recessive 0.7565 0.2272-2.518 0.6492 
 
    
  Additive 0.9689 0.6834-1.374 0.8591 
 
    
  Allelic 
  
0.9722 0.00121 
    
  
     
rs10464870 8 130477823 C 0.2531    0.2284 Dominant 1.163 0.8463-1.598 0.3522 
 
    
  Recessive 1.153 0.6177-2.154 0.6541 
 
    
  Additive 1.126 0.875-1.449 0.3563 
 
    
  Allelic 
  
0.2989 1.079 
    
  
     
rs891835 8 130491752 G 0.2668    0.2384 Dominant 1.124 0.8186-1.543 0.4704 
 
    
  Recessive 1.428 0.7914-2.577 0.2368 
 
    
  Additive 1.143 0.8918-1.466 0.2907 
 
    
  Allelic 
  
0.2415 1.372 
    
  
     
rs6470745 8 130641921 G 0.2045    0.2019 Dominant 1.131 0.8196-1.561 0.4537 
 
    
  Recessive 0.5598 0.2359-1.329 0.1883 
 
    
  Additive 1.022 0.7792-1.342 0.8726 
 
    
  Allelic 
  
0.9055 0.01409 
    
  
     
rs9656979 8 130664407 C 0.4463     0.429 Dominant 0.9949 0.7121-1.39 0.9761 
 
    
  Recessive 1.253 0.8483-1.851 0.2572 
 
    
  Additive 1.072 0.8587-1.338 0.5395 
 
    
  Allelic 
  
0.5324 0.3899 
    
  
     
rs16904140 8 130665643 A 0.2234    0.2204 Dominant 1.07 0.7799-1.469 0.6734 
 
    
  Recessive 0.8109 0.3921-1.677 0.5716 
 
    
  Additive 1.018 0.7841-1.323 0.8914 
 
4 
 
    
  Allelic 
  
0.897 0.01675 
    
  
     
rs4295627 8 130685457 G 0.175    0.1867 Dominant 1.007 0.7228-1.404 0.9661 
 
    
  Recessive 0.3676 0.1239-1.091 0.07126 
 
    
  Additive 0.9176 0.6882-1.223 0.5577 
 
    
  Allelic 
  
0.5886 0.2925 
    
  
     
rs11823971 11 72388561 A 0.09426   0.09129 Dominant 1.085 0.7221-1.629 0.6952 
 
    
  Recessive 0.6434 0.1306-3.17 0.5878 
 
    
  Additive 1.041 0.7195-1.507 0.8299 
 
    
  Allelic 
  
0.8532 0.03425 
    
  
     
rs498872 11 118477367 A 0.2875    0.3126 Dominant 0.8322 0.6085-1.138 0.25 
 
    
  Recessive 0.9407 0.5489-1.612 0.824 
 
    
  Additive 0.8866 0.6965-1.128 0.328 
 
    
  Allelic 
  
0.3293 0.9515 
    
  
     
rs17748 11 118528424 T 0.2045    0.2322 Dominant 0.8394 0.6089-1.157 0.2852 
 
    
  Recessive 0.6521 0.2997-1.419 0.281 
 
    
  Additive 0.8374 0.6391-1.097 0.1979 
 
    
  Allelic 
  
0.2333 1.42 
    
  
     
rs6089953 20 62291008 A 0.2049     0.249 Dominant 0.7755 0.5631-1.068 0.1195 
 
    
  Recessive 0.6218 0.3087-1.252 0.1835 
 
    
  Additive 0.7885 0.6069-1.024 0.07524 
 
    
  Allelic 
  
0.06119 3.505 
    
  
     
rs6010620 20 62309839 A 0.2104 0.2505 Dominant 0.7913 0.5734-1.092 0.1546 
 
5 
 
    
  Recessive 0.6774 0.3429-1.338 0.2622 
 
    
  Additive 0.8092 0.623-1.051 0.1125 
 
    
  Allelic 
  
0.09215 2.836 
    
  
     
rs2297440 20 62312299 T 0.1903 0.242 Dominant 0.7335 0.5225-1.03 0.07344 
 
    
  Recessive 0.589 0.2828-1.227 0.1573 
 
    
  Additive 0.7555 0.5733-0.9957 0.04654 
 
    
  Allelic 
  
0.03246 4.574 
    
  
     
rs4809324 20 62318220 C 0.1379 0.1034 Dominant 1.401 0.9676-2.029 0.07416 
 
    
  Recessive 2.021 0.5735-7.121 0.2737 
 
    
  Additive 1.386 0.991-1.937 0.05651 
 
    
  Allelic 
  
0.05273 3.752 
 
Ψ: MAF=Minor Allele Frequency          £: OR adjusted for age, sex, and country          
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Table S2. Summary results for SNPs unassociated with astrocytoma subtype 
 
SNP Chr. 
Location 
(bp) 
Minor 
allele 
MAF
ψ
 in 
cases 
MAF
ψ
 in 
controls 
Model   OR
£
     95% CI    P CHISQ 
    
  
     
rs7530361 1 100462860 C 0.1477    0.1656 Dominant 0.8099 0.5246-1.25 0.3413 
 
    
  Recessive 1.196 0.3775-3.788 0.7612 
 
    
  Additive 0.8653 0.5905-1.268 0.4582 
 
    
  Allelic 
  
0.4843 0.4891 
    
  
     
rs501700 1 100520311 A 0.1513    0.1607 Dominant 0.8714 0.5523-1.375 0.5542 
 
    
  Recessive 1.26 0.3966-4.001 0.6953 
 
    
  Additive 0.9245 0.6225-1.373 0.6973 
 
    
  Allelic 
  
0.7228 0.1259 
    
  
     
rs2072532 2 40366301 G 0.4773    0.4317 Dominant 1.316 0.8606-2.013 0.205 
 
    
  Recessive 1.214 0.7672-1.919 0.4082 
 
    
  Additive 1.19 0.9125-1.551 0.1993 
 
    
  Allelic 
  
0.1873 1.739 
    
  
     
rs2736100 5 1286516 A 0.4924    0.4958 Dominant 0.7539 0.4876-1.165 0.2037 
 
    
  Recessive 1.298 0.8349-2.019 0.2466 
 
    
  Additive 0.9888 0.7476-1.308 0.9369 
 
    
  Allelic 
  
0.9212 0.009789 
    
  
     
rs2853676 5 1288547 T 0.303    0.2763 Dominant 1.047 0.7102-1.544 0.8161 
 
2 
 
    
  Recessive 1.588 0.8522-2.959 0.1453 
 
    
  Additive 1.131 0.843-1.518 0.4115 
 
    
  Allelic 
  
0.3924 0.7314 
    
  
     
rs6869535 5 40597618 A 0.1641    0.1632 Dominant 0.9237 0.6021-1.417 0.7161 
 
    
  Recessive 2.072 0.6797-6.317 0.2002 
 
    
  Additive 1.011 0.6934-1.475 0.9536 
 
    
  Allelic 
  
0.9708 0.001336 
    
  
     
rs10079250 5 149450132 C 0.04924   0.06394 Dominant 0.7689 0.407-1.453 0.4182 
 
    
  Recessive 2.186e-009  0-inf 0.9993 
 
    
  Additive 0.7602 0.406-1.423 0.3916 
 
    
  Allelic 
  
0.3763 0.7829 
    
  
     
rs2252586 7 54978924 T 0.2652    0.2901 Dominant 0.7586 0.5136-1.12 0.1649 
 
    
  Recessive 1.277 0.6409-2.546 0.4866 
 
    
  Additive 0.8796 0.6438-1.202 0.4202 
 
    
  Allelic 
  
0.4272 0.6304 
    
  
     
rs6969537 7 55082418 A 0.1346    0.1224 Dominant 1.129 0.7183-1.773 0.5996 
 
    
  Recessive 1.205 0.2371-6.125 0.8221 
 
    
  Additive 1.12 0.7413-1.691 0.5913 
 
    
  Allelic 
  
0.5967 0.2801 
    
  
     
rs11979158 7 55159349 G 0.2061    0.1576 Dominant 1.49 0.9933-2.235 0.05391 
 
    
  Recessive 1.541 0.4693-5.061 0.4759 
 
    
  Additive 1.424 0.9948-2.038 0.05341 
 
    
  Allelic 
  
0.06275 3.463 
3 
 
    
  
     
rs10488631 7 128594183 C 0.1174    0.1174 Dominant 1.027 0.6402-1.648 0.912 
 
    
  Recessive 0.7715 0.1624-3.664 0.7441 
 
    
  Additive 1.001 0.6571-1.524 0.9976 
 
    
  
Allelic 
  
0.9992 
1.133e-
006 
    
  
     
rs12531711 7 128617466 G 0.1293     0.117 Dominant 1.171 0.7184-1.908 0.527 
 
    
  Recessive 0.8077 0.1698-3.843 0.7884 
 
    
  Additive 1.11 0.7224-1.705 0.6342 
 
    
  Allelic 
  
0.606 0.2661 
    
  
     
rs10464870 8 130477823 C 0.1962    0.2284 Dominant 0.8254 0.5495-1.24 0.3552 
 
    
  Recessive 0.6168 0.2334-1.63 0.3299 
 
    
  Additive 0.8234 0.5873-1.154 0.2597 
 
    
  Allelic 
  
0.2669 1.233 
    
  
     
rs891835 8 130491752 G 0.2093 0.2384 Dominant 0.8313 0.5557-1.244 0.3685 
 
    
  Recessive 0.7296 0.2952-1.803 0.4946 
 
    
  Additive 0.8448 0.6059-1.178 0.3201 
 
    
  Allelic 
  
0.3264 0.963 
    
  
     
rs6470745 8 130641921 G 0.1641    0.2019 Dominant 0.8657 0.5726-1.309 0.4941 
 
    
  Recessive 0.1466 0.0196-1.097 0.06147 
 
    
  Additive 0.7826 0.5451-1.123 0.1839 
 
    
  Allelic 
  
0.1707 1.877 
    
  
     
rs9656979 8 130664407 C 0.416     0.429 Dominant 0.9272 0.6145-1.399 0.7186 
 
    
  Recessive 0.9248 0.5521-1.549 0.7663 
 
4 
 
    
  Additive 0.9433 0.7124-1.249 0.6839 
 
    
  Allelic 
  
0.7064 0.1419 
    
  
     
rs16904140 8 130665643 A 0.1917    0.2204 Dominant 0.8733 0.5848-1.304 0.5081 
 
    
  Recessive 0.5263 0.1801-1.538 0.2407 
 
    
  Additive 0.843 0.6008-1.183 0.3231 
 
    
  Allelic 
  
0.3135 1.016 
    
  
     
rs4295627 8 130685457 G 0.1477    0.1867 Dominant 0.8255 0.5404-1.261 0.3751 
 
    
  Recessive 0.1668 0.02217-1.255 0.08194 
 
    
  Additive 0.7625 0.5244-1.109 0.1558 
 
    
  Allelic 
  
0.1433 2.143 
    
  
     
rs11823971 11 72388561 A 0.08271   0.09129 Dominant 0.879 0.5153-1.499 0.6358 
 
    
  Recessive 1.112 0.2245-5.512 0.8962 
 
    
  Additive 0.9115 0.5677-1.464 0.7014 
 
    
  Allelic 
  
0.6642 0.1884 
    
  
     
rs498872 11 118477367 A 0.2885    0.3126 Dominant 0.8131 0.5509-1.2 0.2975 
 
    
  Recessive 1.021 0.5314-1.96 0.9513 
 
    
  Additive 0.8895 0.659-1.201 0.4444 
 
    
  Allelic 
  
0.4542 0.5601 
    
  
     
rs17748 11 118528424 T 0.2099    0.2322 Dominant 0.916 0.6152-1.364 0.6655 
 
    
  Recessive 0.5087 0.1739-1.489 0.2173 
 
    
  Additive 0.8681 0.6205-1.214 0.4089 
 
    
  Allelic 
  
0.4456 0.5817 
 
5 
 
Ψ: MAF=Minor Allele Frequency          £: OR adjusted for age, sex, and country          
1 
 
Table S3. Summary results for SNPs unassociated with non-astrocytoma subtypes 
 
SNP Chr. 
Location 
(bp) 
Minor 
allele 
MAF
ψ
 in 
cases 
MAF
ψ
 in 
controls 
Model OR
£
 95% CI P CHISQ 
    
  
     
rs7530361 1 100462860 C 0.1396    0.1656 Dominant 0.8026 0.5004-1.287 0.3617 
 
    
  Recessive 0.7271 0.1586-3.333 0.6816 
 
    
  Additive 0.817 0.5339-1.25 0.3517 
 
    
  Allelic 
  
0.3421 0.9025 
    
  
     
rs501700 1 100520311 A 0.1442    0.1607 Dominant 0.866 0.5328-1.408 0.5617 
 
    
  Recessive 0.7255 0.1583-3.326 0.6796 
 
    
  Additive 0.869 0.5639-1.339 0.5243 
 
    
  Allelic 
  
0.5567 0.3455 
    
  
     
rs2072532 2 40366301 G 0.4398    0.4317 Dominant 1.508 0.941-2.416 0.08778 
 
    
  Recessive 0.7903 0.4447-1.405 0.4225 
 
    
  Additive 1.115 0.8256-1.505 0.4783 
 
    
  Allelic 
  
0.8285 0.04695 
    
  
     
rs2853676 5 1288547 T 0.2617    0.2763 Dominant 0.9002 0.5865-1.382 0.6307 
 
    
  Recessive 0.9824 0.4376-2.206 0.9657 
 
    
  Additive 0.9332 0.6636-1.312 0.6908 
 
    
  Allelic 
  
0.6656 0.1868 
    
  
     
rs6869535 5 40597618 A 0.1697    0.1632 Dominant 1.012 0.6412-1.598 0.9584 
 
2 
 
    
  Recessive 0.8717 0.1822-4.17 0.8635 
 
    
  Additive 1 0.6607-1.514 0.9999 
 
    
  Allelic 
  
0.814 0.05535 
    
  
     
rs10079250 5 149450132 C 0.07407   0.06394 Dominant 1.257 0.6855-2.303 0.4602 
 
    
  Recessive 2.145e-009 0-inf 0.9993 
 
    
  Additive 1.218 0.6728-2.204 0.5152 
 
    
  Allelic 
  
0.5876 0.2941 
    
  
     
rs2252586 7 54978924 T 0.2454    0.2901 Dominant 0.77 0.5012-1.183 0.233 
 
    
  Recessive 0.8852 0.3769-2.079 0.7795 
 
    
  Additive 0.8259 0.5816-1.173 0.2849 
 
    
  Allelic 
  
0.1874 1.738 
    
  
     
rs6969537 7 55082418 A 0.1468    0.1224 Dominant 1.389 0.8617-2.24 0.1774 
 
    
  Recessive 2.685e-009 0-inf 0.9984 
 
    
  Additive 1.257 0.8045-1.965 0.3149 
 
    
  Allelic 
  
0.3286 0.9543 
    
  
     
rs11979158 7 55159349 G 0.1389    0.1576 Dominant 0.8264 0.5105-1.338 0.438 
 
    
  Recessive 0.8848 0.1845-4.242 0.8784 
 
    
  Additive 0.8477 0.5475-1.312 0.4586 
 
    
  Allelic 
  
0.4925 0.471 
    
  
     
rs10488631 7 128594183 C 0.1065    0.1174 Dominant 0.8154 0.4766-1.395 0.4564 
 
    
  Recessive 0.6751 0.1403-3.248 0.624 
 
    
  Additive 0.8262 0.5169-1.321 0.4251 
 
    
  Allelic 
  
0.6501 0.2057 
3 
 
    
  
     
rs12531711 7 128617466 G 0.1048     0.117 Dominant 0.8133 0.4701-1.407 0.4601 
 
    
  Recessive 0.6777 0.141-3.257 0.6271 
 
    
  Additive 0.8255 0.5128-1.329 0.4299 
 
    
  Allelic 
  
0.6161 0.2514 
    
  
     
rs6470745 8 130641921 G 0.2523    0.2019 Dominant 1.543 1.009-2.36 0.04533 
 
    
  Recessive 1.061 0.4152-2.709 0.9022 
 
    
  Additive 1.341 0.9536-1.886 0.09157 
 
    
  Allelic 
  
0.09774 2.742 
    
  
     
rs9656979 8 130664407 C 0.482     0.429 Dominant 1.101 0.6968-1.741 0.6794 
 
    
  Recessive 1.755 1.071-2.877 0.02563 
 
    
  Additive 1.264 0.9367-1.705 0.1255 
 
    
  Allelic 
  
0.1519 2.053 
    
  
     
rs16904140 8 130665643 A 0.2613    0.2204 Dominant 1.365 0.8956-2.081 0.1477 
 
    
  Recessive 1.182 0.4929-2.836 0.7075 
 
    
  Additive 1.256 0.8964-1.759 0.1856 
 
    
  Allelic 
  
0.1906 1.713 
    
  
     
rs4295627 8 130685457 G 0.2083    0.1867 Dominant 1.288 0.8312-1.996 0.2574 
 
    
  Recessive 0.6115 0.1763-2.121 0.4383 
 
    
  Additive 1.136 0.7867-1.639 0.4974 
 
    
  Allelic 
  
0.4654 0.533 
    
  
     
rs1063192 9 22003367 G 0.5229    0.4506 Dominant 1.253 0.7802-2.012 0.3508 
 
    
  Recessive 1.594 0.9966-2.55 0.05169 
 
4 
 
    
  Additive 1.288 0.9646-1.72 0.08627 
 
    
  Allelic 
  
0.05402 3.712 
    
  
     
rs2157719 9 22033366 C 0.5093    0.4383 Dominant 1.324 0.8259-2.122 0.2438 
 
    
  Recessive 1.527 0.9445-2.468 0.0842 
 
    
  Additive 1.292 0.9665-1.728 0.08364 
 
    
  Allelic 
  
0.05833 3.584 
    
  
     
rs1412829 9 22043926 G 0.5    0.4338 Dominant 1.253 0.7896-1.989 0.3382 
 
    
  Recessive 1.532 0.9485-2.474 0.08117 
 
    
  Additive 1.267 0.9494-1.691 0.108 
 
    
  Allelic 
  
0.07408 3.19 
    
  
     
rs4977756 9 22068652 G 0.4673    0.4224 Dominant 1.11 0.7018-1.756 0.6556 
 
    
  Recessive 1.4 0.844-2.324 0.1924 
 
    
  Additive 1.167 0.8676-1.571 0.3069 
 
    
  Allelic 
  
0.231 1.434 
    
  
     
rs11823971 11 72388561 A 0.1081   0.09129 Dominant 1.419 0.8441-2.385 0.1867 
 
    
  Recessive 3.647e-009 0-inf 0.9983 
 
    
  Additive 1.269 0.7834-2.054 0.3334 
 
    
  Allelic 
  
0.4397 0.5971 
    
  
     
rs498872 11 118477367 A 0.2864    0.3126 Dominant 0.8545 0.5609-1.302 0.4641 
 
    
  Recessive 0.8299 0.3899-1.766 0.6285 
 
    
  Additive 0.8778 0.6322-1.219 0.4365 
 
    
  Allelic 
  
0.4469 0.5786 
    
  
     
5 
 
rs17748 11 118528424 T 0.1982    0.2322 Dominant 0.767 0.4953-1.188 0.2344 
 
    
  Recessive 0.8286 0.3069-2.237 0.7105 
 
    
  Additive 0.8104 0.561-1.171 0.2625 
 
    
  Allelic 
  
0.2748 1.193 
    
  
     
rs6089953 20 62291008 A 0.2342     0.249 Dominant 0.9747 0.6365-1.493 0.906 
 
    
  Recessive 0.7992 0.3233-1.976 0.6275 
 
    
  Additive 0.9504 0.6737-1.341 0.7721 
 
    
  Allelic 
  
0.6461 0.2109 
    
  
     
rs6010620 20 62309839 A 0.2361    0.2505 Dominant 0.9816 0.6375-1.511 0.9329 
 
    
  Recessive 0.8028 0.3236-1.992 0.6356 
 
    
  Additive 0.9552 0.6749-1.352 0.796 
 
    
  Allelic 
  
0.6578 0.1962 
    
  
     
rs2297440 20 62312299 T 0.2108     0.242 Dominant 0.8803 0.56-1.384 0.5805 
 
    
  Recessive 0.6877 0.258-1.833 0.454 
 
    
  Additive 0.8708 0.6042-1.255 0.458 
 
    
  Allelic 
  
0.345 0.8917 
    
  
     
rs4809324 20 62318220 C 0.1216    0.1034 Dominant 1.203 0.726-1.994 0.4729 
 
    
  Recessive 0.7842 0.08663-7.099 0.8288 
 
    
  Additive 1.158 0.7253-1.849 0.539 
 
    
  Allelic 
  
0.4282 0.6276 
 
Ψ: MAF=Minor Allele Frequency          £: OR adjusted for age, sex, and country          
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Table S4. Number of subjects for each genotype of SNPs associated with pediatric brain 
tumors 
SNP Gene Genotype Cases Controls 
All brain tumors 
 
   
rs2736100 TERT CC 76 113 
  CA 103 256 
  AA 61 109 
rs1063192 CDKN2BAS AA 56 150 
 CDKN2B AG 116 212 
  GG 67 104 
rs2157719 CDKN2BAS TT 58 159 
  TC 117 219 
  CC 63 100 
rs1412829 CDKN2BAS AA 62 159 
  AG 118 221 
  GG 63 96 
rs4977756 CDKN2BAS AA 62 164 
  AG 121 223 
  GG 55 90 
Astrocytoma     
     
rs1063192 CDKN2BAS AA 27 150 
 CDKN2B AG 70 212 
  GG 33 104 
rs2157719 CDKN2BAS TT 29 159 
  TC 69 219 
  CC 32 100 
rs1412829 CDKN2BAS AA 31 159 
  AG 69 221 
  GG 32 69 
rs4977756 CDKN2BAS AA 29 164 
  AG 73 223 
  GG 29 90 
rs6089953 RTEL1 GG 90 277 
  GA 38 170 
  AA 5 35 
rs6010620 RTEL1 GG 88 272 
  GA 38 168 
  AA 6 35 
rs2297440 RTEL1 CC 86 258 
  CT 33 145 
2 
 
 
 
  TT 5 33 
rs4809324 RTEL1 TT 96 381 
  TC 32 88 
  CC 4 5 
Other 
 
   
rs2736100 TERT CC 38 113 
  CA 46 256 
  AA 25 109 
rs10464870 CCDC26 TT 52 287 
  TC 47 159 
  CC 12 29 
rs891835 CCDC26 TT 51 277 
  TG 43 168 
  GG 15 29 
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            Table S5. Summary results for SNPs associated with pediatric brain tumors in Denmark 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Chr. Gene 
Location 
(bp) 
Minor 
allele 
MAF
a
 
in cases 
MAF
a
 in 
controls 
Model OR
b 
95% CI P CHISQ 
            
rs2736100 5 TERT 1286516 A 0.47 0.48 Dominant 0.76  0.38-1.50 0.427 
 
       
Recessive 1.18  0.58-2.41 0.647 
 
       
Additive 0.95 0.62-1.47 0.826 
 
       
Allelic 
  
0.864 0.03 
 rs1063192 9 CDKN2BAS 22003367 G 0.54 0.49 Dominant 1.12 0.56-2.26 0.751 
 
  
CDKN2B 
    
Recessive 1.56 0.76-3.21 0.227 
 
       
Additive 1.21 0.80-1.82 0.362 
 
       
Allelic 
  
0.33 0.95 
rs2157719 9 CDKN2BAS 22033366 C 0.54 0.46 Dominant 1.78  0.85-3.73 0.125 
 
       
Recessive 1.27  0.63-2.56 0.496 
 
       
Additive 1.34 0.87-2.05 0.179 
 
       
Allelic 
  
0.159 1.96 
rs1412829 9 CDKN2BAS 22043926 G 0.52 0.46 Dominant 1.45  0.73-2.91 0.283 
 
       
Recessive 1.19 0.60-2.38 0.611 
 
       
Additive 1.23 0.81-1.85 0.336 
 
       
Allelic 
  
0.315 1.01 
rs4977756 9 CDKN2BAS 22068652 G 0.48 0.43 Dominant 1.61  0.81-3.19 0.174 
 
       
Recessive 1.04 0.49-2.20 0.909 
 
       
Additive 1.23  0.80-1.88 0.343 
 
       
Allelic 
  
0.337 0.92 
2 
 
           a: MAF=Minor Allele Frequency          b: OR adjusted for age, and sex  
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           Table S6. Summary results for SNPs associated with pediatric brain tumors in Norway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Chr. Gene 
Location 
(bp) 
Minor 
allele 
MAF
a
 
in cases 
MAF
a
 in 
controls 
Model OR
b 
95% CI P CHISQ 
            
rs2736100 5 TERT 1286516 A 0.42 0.58 Dominant 0.42 0.12-1.41 0.161 
 
       
Recessive 0.39 0.13-1.17 0.093 
 
       
Additive 0.50 0.24-1.03 0.059 
 
       
Allelic 
  
0.052 3.78 
 rs1063192 9 CDKN2BAS 22003367 G 0.48 0.43 Dominant 2.06 0.67-6.34 0.206 
 
  
CDKN2B 
    
Recessive 1.02 0.31-3.31 0.979 
 
       
Additive 1.33 0.68-2.61 0.407 
 
       
Allelic 
  
0.545 0.37 
rs2157719 9 CDKN2BAS 22033366 C 0.50 0.40 Dominant 2.19  0.73-6.56 0.161 
 
       
Recessive 1.49  0.47-4.73 0.493 
 
       
Additive 1.57 0.79-3.08 0.193 
 
       
Allelic 
  
0.244 1.36 
rs1412829 9 CDKN2BAS 22043926 G 0.48 0.39 Dominant 2.29  0.77-6.83 0.138 
 
       
Recessive 1.19 0.36-3.97 0.774 
 
       
Additive 1.49 0.76-2.94 0.248 
 
       
Allelic 
  
0.317 1.00 
rs4977756 9 CDKN2BAS 22068652 G 0.44 0.40 Dominant 1.70 0.59-4.91 0.326 
 
       
Recessive 0.83 0.24-2.93 0.774 
 
       
Additive 1.18 0.61-2.31 0.620 
 
       
Allelic 
  
0.710 0.14 
1 
 
           a: MAF=Minor Allele Frequency          b: OR adjusted for age, and sex  
 1 
 
          Table S7. Summary results for SNPs associated with pediatric brain tumors in Sweden 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Chr. Gene 
Location 
(bp) 
Minor 
allele 
MAF
a
 
in cases 
MAF
a
 in 
controls 
Model OR
b 
95% CI P CHISQ 
            
rs2736100 5 TERT 1286516 A 0.48 0.50 Dominant 0.58  0.33-1.01 0.055 
 
       
Recessive 1.44  0.81-2.55 0.216 
 
       
Additive 0.92 0.65-1.31 0.651 
 
       
Allelic 
  
0.587 0.29 
 rs1063192 9 CDKN2BAS 22003367 G 0.57 0.46 Dominant 1.77 1.02-3.09 0.044 
 
  
CDKN2B 
    
Recessive 1.76 0.97-3.18 0.061 
 
       
Additive 1.53 1.08-2.18 0.018 
 
       
Allelic 
  
0.016 5.75 
rs2157719 9 CDKN2BAS 22033366 C 0.54 0.45 Dominant 1.64  0.93-2.88 0.089 
 
       
Recessive 1.68  0.96-2.94 0.068 
 
       
Additive 1.45 1.03-2.05 0.032 
 
       
Allelic 
  
0.029 4.73 
rs1412829 9 CDKN2BAS 22043926 G 0.54 0.44 Dominant 1.57  0.89-2.75 0.113 
 
       
Recessive 1.85 1.06-3.25 0.031 
 
       
Additive 1.49 1.05-2.09 0.024 
 
       
Allelic 
  
0.021 5.34 
rs4977756 9 CDKN2BAS 22068652 G 0.53 0.44 Dominant 1.57  0.89-2.77 0.122 
 
       
Recessive 1.72 0.96-3.08 0.067 
 
       
Additive 1.45  1.02-2.07 0.039 
 
       
Allelic 
  
0.039 4.28 
 2 
 
          
          a: MAF=Minor Allele Frequency          b: OR adjusted for age, and sex  
